All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
How does the mutation profile differ between patients with MDS–AML and de novo AML?
Bookmark this article
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to James Yu, AdventHealth Orlando, Orlando, US. We asked, How does the mutation profile differ between patients with MDS–AML and de novo AML?
How does the mutation profile differ between patients with MDS–AML and de novo AML?
In this video, Yu discusses a study comparing the differences in chromosomal mutations between AML with myelodysplasia-related changes (MRC) and AML with no clinical history of prior myelodysplastic syndrome. Results indicate that the non-MRC group exhibited a more dynamic genomic profile when compared to the AML-MRC group.
Your opinion matters
42 votes - 4 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox